NCT06740916 Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance
| NCT ID | NCT06740916 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Siriraj Hospital |
| Condition | Myeloproliferative Neoplasms (MPN) |
| Study Type | INTERVENTIONAL |
| Enrollment | 240 participants |
| Start Date | 2024-12-12 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 240 participants in total. It began in 2024-12-12 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients with myeloproliferative neoplasm (MPN) could have laboratory aspirin resistance and then increasing dose of aspirin from once daily to twice daily regimen is suggested. However, it is not routinely recommended to perform platelet function testing to determine aspirin resistance in MPN patients. Moreover, it is not known whether increasing dose of aspirin would always correct aspirin resistance and significantly prevent the thrombotic events in MPN patients. Therefore, this study aims to compare the efficacy of once daily versus twice daily aspirin in high-risk MPN patients with aspirin resistance. MPN patients with laboratory aspirin resistance will be included in this prospective randomized study and platelet function testing will be repeated at one and six months later. Clinical thrombosis and side effect from aspirin will be recorded for at least 2 years after intervention.
Eligibility Criteria
Inclusion Criteria: * Philadelphia negative Myeloproliferative neoplasms aged at least 18 years old Exclusion Criteria: * Concomitant other active malignancy or cured less than 6 months * Platelet count less than 50,000/microL * Receiving anticoagulant * Active peptic ulcer * Active bleeding or Planning to undergo procedure/operation with bleeding risk * No laboratory aspirin resistance with LTA method
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06740916 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myeloproliferative Neoplasms (MPN). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06740916 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 240 participants.
Is NCT06740916 currently recruiting?
Yes, NCT06740916 is actively recruiting participants. Contact the research team at dryingyong@gmail.com for enrollment information.
Where is the NCT06740916 trial being conducted?
This trial is being conducted at Bangkok Noi, Thailand.
Who is sponsoring the NCT06740916 clinical trial?
NCT06740916 is sponsored by Siriraj Hospital. The trial plans to enroll 240 participants.